Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. decreased its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 384,771 shares of the medical technology company's stock after selling 47,085 shares during the period. Rockefeller Capital Management L.P. owned about 0.27% of Alphatec worth $3,532,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of ATEC. Barclays PLC boosted its position in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company's stock worth $948,000 after purchasing an additional 133,653 shares in the last quarter. Franklin Resources Inc. increased its holdings in Alphatec by 299.3% in the 3rd quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company's stock worth $343,000 after acquiring an additional 48,308 shares in the last quarter. State Street Corp raised its position in Alphatec by 10.1% during the third quarter. State Street Corp now owns 3,138,960 shares of the medical technology company's stock worth $17,453,000 after acquiring an additional 287,350 shares during the period. Congress Asset Management Co. lifted its holdings in Alphatec by 235.4% during the fourth quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock valued at $3,993,000 after purchasing an additional 305,296 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Alphatec in the third quarter valued at about $69,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Up 1.3 %

Shares of NASDAQ ATEC traded up $0.15 during midday trading on Thursday, hitting $11.36. The company's stock had a trading volume of 330,198 shares, compared to its average volume of 2,042,046. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $13.79. The business's fifty day simple moving average is $10.38 and its two-hundred day simple moving average is $9.57. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of -8.85 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million for the quarter, compared to analysts' expectations of $172.74 million. On average, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ATEC shares. Piper Sandler lifted their price objective on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Barclays raised their price objective on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a report on Wednesday, January 22nd. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Finally, Needham & Company LLC restated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Alphatec currently has an average rating of "Moderate Buy" and a consensus price target of $17.67.

Insider Buying and Selling

In other news, EVP David Sponsel sold 33,732 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Patrick Miles sold 50,000 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00. Following the transaction, the chief executive officer now owns 6,152,544 shares of the company's stock, valued at approximately $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 272,113 shares of company stock worth $3,121,225. Company insiders own 22.80% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.